drugset
drugset / Trial / NCT02325050

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

NCT02325050 ↗

Phase 1 Completed 164 enrolled Janssen Vaccines & Prevention B.V.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous and homologous prime-boost vaccine regimens in healthy adult participants.

Timeline

Start
2015-01-08
Primary completion
2015-07-02
Completion
2017-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ADENOVIRUS TYPE 26 ENCODING EBOLA VIRUS GLYCOPROTEIN Vaccine 5e+10 unknown Intramuscular
Subject ADENOVIRUS TYPE 26 ENCODING EBOLA VIRUS GLYCOPROTEIN Vaccine 1e+11 unknown Intramuscular
Subject MVA-BN-Filo Vaccine 1e+08 unknown Intramuscular
Subject MVA-BN-Filo Vaccine 4.4e+08 unknown Intramuscular

Indications

No indication recorded.